2025 ESGO-ESTRO-ESP Endometrial cancer guidelines

As part of its mission to improve the quality of care for women with gynaecological cancers, the European Society of Gynaecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) decided to update the ESGO-ESTRO-ESP evidence-based guidelines published in 2021 by incorporating the revised FIGO staging system published in 2023 and the large body of new evidence addressing the management of endometrial carcinoma. The developmental process of these guidelines was based on a systematic literature review and critical appraisal process involving an international multidisciplinary development group consisting of 30 experts from relevant disciplines (gynaecological oncology, radiation and medical oncology and pathology) as well as a patient representative, led by Prof. Nicole Concin (ESGO), Prof. Remi Nout (ESTRO) and Prof. Xavier Matias-Guiu (ESP).

The guidelines were reviewed by independent international practitioners and three patient representatives from Asia, Europe, North Africa, North America, the Middle East, and South America.

The article of the updated guidelines is planned to be published in Q2 2025.

2021 guidelines article is available here: ESGO-ESTRO-ESP Endometrial cancer guidelines 2021

 

2025 Update Working Group

The European Society of Gynaecological Oncology (ESGO), European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) would like to express their sincere gratitude to the international experts panel, who devoted their time and effort to the development of  the update of ESGO-ESTRO-ESP Guidelines for the management of patients with endometrial carcinoma.

Expert	Country	Institution
Concin Nicole	Austria	Department of Gynecology and Obstetrics, Medical University of Vienna, Austria
Nout Remi	the Netherlands	Radiotherapy, Erasmus MC Cancer Centre, Rotterdam, The Netherlands
Matias-Guiu Xavier	Spain	Department of Pathology, Hospital Universitari Arnau de Vilanova, University of Lleida, Institute of Biomedical Research of Lleida (Irblleida), Lleida, Spain Department of Pathology, Hospital Universitari de Bellvitge, Bellvitge Institute of Biomedical Research (IDIBELL), University of Barcelona, Barcelona, Spain
Francois Planchamp	France	Institut Bergonié, Bordeaux, France
Abu-Rustum Nadeem	United States	Chief, Gynecology Service, Founder’s Chair Gynecologic Oncology,  Professor, Weill Cornell Medical College Memorial Sloan Kettering Cancer Center 1275 York Avenue, H-1305,  New York, NY 10065
BosseTjalling	the Netherlands	Department of pathology, Leiden University Medical Center, The Netherlands.
Cibula David	Czech Republic	Department of Gynaecology, Obstetrics and Neonatology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic
Colombo Nicoletta	Italy	Gynecologic Program , European Institute of oncology IRCCS, Milan Department of Medicine and Surgery, University of Milan-Bicocca, Italy
Creutzberg Carien	the Netherlands	Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands
Espenel Sophie	France	Department of Radiation Oncology, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94800 Villejuif, France
Fagotti Anna	Italy	Gynecologic Oncology Unit, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Università Cattolica del Sacro Cuore Rome Italy
Fotopoulou Christina	United Kingdom	Imperial College London Faculty of Medicine, Department of Surgery and Cancer, London (United Kingdom)
Gatius Sonia	Spain	Pathology Department and Oncological Pathology Research Group. Hospital Universitari Arnau de Vilanova de Lleida, Universitat de Lleida, IRB Lleida. CIBERONC
González-Martín Antonio	Spain	Medical Oncology Department, Cancer Center Clinica Universidad de Navarra, Madrid, Spain
Chargari Cyrus	France	Radiation Oncology department, University Hospital Pitié Salpêtrière, Paris, France
Lax Sigurd	Austria	Pathology, Hospital Graz II, Graz, Austria Pathology, Johannes Kepler University, Linz, Austria
Ledermann Jonathan	United Kingdom	Cancer Research UK and UCL Cancer Centre, UCL Cancer Institute, University College London, London, United Kingdom.
Levy Bar	Israel	Management, HaBait Shel Bar - Israel Women's Cancer Association (RA) Department of Public Health, Faculty of Medicine, Tel Aviv University
Lorusso Domenica	Italy	Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy
Macchia Gabriella	Italy	Radiation Oncology Unit, Responsible Research Hospital, Campobasso, Molise, Italy
Marth Christian	Austria	Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria
Mirza Mansoor	Denmark	Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Morice Philippe	France	Department of surgery, Gustave Roussy Cancer Campus, Villejuif, France University Paris Saclay, Le Kremlin Bicêtre, France
Oaknin Ana	Spain	Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, SpainOncology Data Science (ODysSey) VHIO, Barcelona, Spain
Raspollini Maria Rosaria	Italy	Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Via Pieraccini, 6 – 50129 Florence - Italy
Sehouli Jalid	Germany	Department of Gynecology with Center for Oncological Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany North-Eastern German Society of Gynaecologic Oncology (NOGGO), Berlin, Germany
Schwameis Richard	Austria	Department of Gynecology and Obstetrics, Medical University of Vienna, Austria
Sturdza Alina	Austria	Medical University of Vienna, Department of Radiation Oncology, Comprehensive Cancer Centre Vienna
Taylor Alexandra	United Kingdom	Dept of Gynaecology Oncology, The Royal Marsden NHS Foundation Trust, UK
Vergote Ignace	Belgium	Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium – European Union
Westermann Anneke	the Netherlands	Amsterdam University Medical Centers, Department of Medical Oncology, Amsterdam, Netherlands
Wimberger Pauline	Germany	Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, and NCT Dresden, Dresden, Germany Fetscherstr. 74, 01307 Dresden, Germany

 

External reviewers

225 reviewers - 50 countries

ESGO would also like to thank external reviewers who have taken the time to provide their feedback on the document elaborated in the framework of the ESGO-ESTRO-ESP Endometrial cancer guidelines.

List of external reviewers